Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ABM Industries

Dover

Lowe's

Parker-Hannifin

These stocks have increased their dividends for 50-plus years. Here's why they should remain long-term winners.

5 'Top Dividend Kings' to Buy and Hold Forever

Johnson & Johnson has short- and intermediate-term headwinds, but still present a compelling long-term case for investors. 
The post Should Johnson & Johnson Investors Worry About Opioid Lawsuits?

Should Johnson & Johnson Investors Worry About Opioid Lawsuits?

Johnson and Johnson stock has yet to fully absorb the bad news, fines, and reputational damage inflicted by recent settlements.
The post There’s a Lot More Trouble Looming for JNJ Stock Than You Might Think appeared first on InvestorPlace.

There’s a Lot More Trouble Looming for JNJ Stock Than You Might Think

Johnson & Johnson & Johnson's current low share price reflects fear in the market of large opioid-related claims.

Johnson & Johnson: Opportunity Beckons - Know When To Strike

The recent  ruling against Johnson & Johnson (NYSE:JNJ) put some pressure on JNJ stock. Here’s a good way to prevent huge losses.

Buy This If You Like Johnson & Johnson Stock But Hate the Lawsuits  

J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

Johnson & Johnson stock remains under pressure from various lawsuits, but on Thursday an analyst called for the Dow Jones pharmaceutical company to report outsized third-quarter results.
The post Johnson & Johnson Could Shrug Off Pressure In Third Quarter — Here's Why appeared first on Investor's Business Daily.

Johnson & Johnson Could Shrug Off Pressure In Third Quarter — Here's Why

Allergan

Sientra

As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

FDA Warns About Safety of Breast Implant: 3 Stocks at Risk

JNJ stock is supported by strong fundamentals, but weak optics will keep a lid on shares for the foreseeable future. 
The post JNJ Stock Is Undervalued, but Not Compelling Given These Headwinds appeared first on InvestorPlace.

JNJ Stock Is Undervalued, but Not Compelling Given These Headwinds

J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.

J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis

American Airlines

Delta Air Lines

Southwest Airlines

Teva Pharmaceutical

United Continental Hlds

These stocks don't match the qualities Buffett typically looks for in an investment.

Warren Buffett's Most Baffling Stock Holdings

AbbVie

Bristol-Myers

Cardinal Health

Health Care Select Sector SPDR Fund

The Healthcare Sector has been a top three sector for me due to earnings growth outlook, and it still is.

Healthcare: Still A Great Buy For Dividend Growth Investors

J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.

J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients

Johnson & Johnson (NYSE:JNJ) is the leader in the prostate cancer hormonal therapy market, with Zytiga sales of $3.5 billion in 2018. Other key drugs include Astellas’ Xtandi, and AbbVie’s Lupron.

Johnson & Johnson's $3.5 Billion Prostate Cancer Drug Sales At Risk?

A big question for every Johnson & Johnson's shareholder takes on ever more significance.

Johnson & Johnson's Definitive Tests (Part 1)

Alexion Pharma

Bausch Health Companies Inc

Cigna

CVS Health

Intercept Pharma

Eli Lilly

Pfizer

PRA Health Sciences

Eli Lilly, Alexion and AbbVie are just some of the top healthcare stocks to buy here, now that disappointing news has driven them to cheap prices.

10 Healthcare Stocks to Buy Despite the Headlines

A sizable portion of litigation costs has been imputed in JNJ's current share price, which I believe is overblown.

Johnson & Johnson: An Emerging Sum Of The Parts Investment Case

Investors need to be careful about which pharmaceutical stocks they own.

How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks?

Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).

J&J's Stelara Gets Approval in EU for Ulcerative Colitis

PepsiCo

Coke's dividend is sweet, but these two stocks offer comparable yields and better long-term prospects.

Forget Coca-Cola: Here Are 2 Better Dividend Stocks

Disney

NextEra Energy

These income stocks are phased by virtually nothing, making them incredibly safe bets to deliver over the long run.

3 Surefire Dividend Stocks to Pass On to Your Kids or Grandkids

There's a good chance that Johnson & Johnson will be overwhelmed by two huge legal battles, causing JNJ stock to drop tremendously. 
The post It’s Time to Short Johnson & Johnson Stock appeared first on InvestorPlace.

It’s Time to Short Johnson & Johnson Stock

Tesla

Investors should wait out these three big names. There may be better entry points later in the year.

3 Large-Cap Stocks to Sell in September

Endo International

Mallinckrodt PLC

Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.

Will Opioid Litigation Take its Toll on Pharma Companies?

Dow component Johnson & Johnson is trading dangerously close to 2018 support after yet another legal setback.

News for Johnson & Johnson Stock (JNJ)